Senior Management Team

Senior Management Team

John Sedor

Chairman and Chief Executive Officer

READ BIOGRAPHY

John Sedor has served as our Chairman and Chief Executive Officer since July 2018. Mr. Sedor has been Chairman of the Board and Chief Executive Officer of Pernix Therapeutics since July 2016 and Chairman and Chief Executive Officer of SEDOR Pharmaceuticals, LLC since 2014. Mr. Sedor served as President, Chief Executive Officer and a director of Cangene Corporation, a fully integrated developer and manufacturer of immune therapeutics, from 2011 until its acquisition by Emergent Biosolutions in February 2014. Prior to that, from 2008 until 2011, Mr. Sedor served as President and Chief Executive Officer of CPEX Pharmaceuticals, or CPEX, after its 2008 spin-off from Bentley Pharmaceuticals, Inc., or Bentley, and until its 2011 acquisition by Footstar, Inc. Mr. Sedor was President of Bentley from 2005 until the spin-off of CPEX. From 2001 to May 2005, he was President and CEO of Sandoz, Inc. (a division of Novartis AG). From 1998-2001 Mr. Sedor was President and Chief Executive Officer at Verion, Inc., a drug delivery company. Previously, Mr. Sedor served as President and Chief Executive Officer at Centeon, LLC. Mr. Sedor holds a Bachelor of Science degree in Pharmacy/Chemistry from Duquesne University, and has studied strategic marketing at both Northwestern University’s Kellogg Graduate School of Management and Harvard Business School. He has also attended Harvard’s Executive Forum.

CLOSE

Kenneth R. Piña

Executive Vice President

READ BIOGRAPHY

Ken Piña has served as our Executive Vice President since July 2018. Mr. Piña has been the Senior Vice President, Chief Legal & Compliance Officer and Corporate Secretary of Pernix Therapeutics since January 2017. Most recently, Mr. Piña was a Founder and the Managing Principal of Core Risks Ltd. (CRL), a global compliance and risk management consultancy firm that was acquired by Jardine Lloyd Thompson. He formerly served as the Senior Vice President, Chief Legal Officer and Secretary for Henkel Corporation. Before joining Henkel, Mr. Piña served as Vice President, General Counsel and Secretary of Rhone-Poulenc Rorer Pharmaceuticals Inc. Mr. Piña received his Juris Doctorate from the Dickinson School of Law, Pennsylvania State University, and earned his B.S. degree from the Rutgers University College of Pharmacy. He has served as an adjunct professor of food and drug law at Temple University and as a lecturer in law at the Villanova School of Law. He is also co-editor of the industry text, An Introduction to Food and Drug Law and Regulation (FDLI), now in its fifth edition.

CLOSE

Angus Smith

Executive Vice President

READ BIOGRAPHY

Angus Smith has served as our Executive Vice President since July 2018. Mr. Smith has been Senior Vice President, Chief Business Officer and Principal Financial Officer for Pernix Therapeutics since February 2018. Prior to joining Pernix, Mr. Smith served as a Director in the Healthcare Investment Banking Group at Cantor Fitzgerald, a financial services firm, where he worked from October 2011 to September 2014. Mr. Smith previously held several positions of increasing responsibility in the Healthcare Investment Banking group at Gleacher & Company, a financial advisory firm, and various predecessor firms from July 2005 to August 2011. During his investment banking tenure, Mr. Smith worked on a variety of transactions, providing advice to specialty pharmaceutical and healthcare companies regarding mergers and acquisitions, initial public offerings, follow-on offerings, debt offerings, private placements and debt restructuring transactions. Mr. Smith earned a B.A. in Mathematical Economics from Colgate University.

CLOSE

Salma Jutt

Senior Vice President, Chief Commercial Officer

READ BIOGRAPHY

Salma Jutt brings over 20 years of commercial experience managing US and Global P&Ls for highly successful franchises and brands across sales, marketing, business intelligence, distribution and pricing. She began her career in sales at Boehringer Ingelheim and spent ~15 years at Allergan in progressive commercial leadership roles prior to her current appointment as Senior Vice President, Chief Commercial Officer for Nalpropion Pharmaceuticals (Nalpropion acquired the assets of Orexigen Therapeutics in July 2018). Salma has deep therapeutic experience bringing scientifically differentiated treatments to consumers and physicians across Women’s Health, CNS, Endocrinology, Bariatrics, Medical Aesthetics, Plastic Surgery, Dermatology and Ophthalmology. Her experience spans cash pay and reimbursed markets, complex pricing strategies, highly competitive categories, patient and HCP advocacy, DTC, digital and social patient acquisition and innovative distribution channels such as telemedicine and e-commerce. In her current role she leads worldwide commercial operations across 68 countries, driving double digit growth in prescriptions and net sales for Contrave, the #1 prescribed weight loss brand.

Salma has also held leadership roles in sales and marketing for Botox® Cosmetic, Juvederm Voluma® and Lumigan® and served on the Allergan Facial Aesthetics Leadership Team across an $1B+ business. In her time at Allergan she led the organization wide launch of Latisse® and created a brand-new market category. With her leadership Latisse® became one of the top products in medical aesthetics. She served as franchise lead for the Topical Aesthetics Business where she built and led an integrated team across a P&L that included sales, marketing, manufacturing and R&D. In that role she was also commercial lead for M&A focused on skincare acquisition assessments one of which set the stage for Allergan acquiring SkinMedica®.

CLOSE

Monica Forbes

Vice President, Chief Financial Officer

READ BIOGRAPHY

Monica Forbes joined Orexigen in 2014 and is currently Vice President and Chief Financial Officer. Over the last 3.5 years, Monica has made tremendous contributions to the organization, guiding the development and oversight of the company’s budget process, supporting the financial planning and analysis for the U.S. business and working with the executive team on our strategic outreach process. Monica has over 15 years of financial planning & analysis experience in the biopharmaceutical and telecommunications industries. She joined Orexigen from Amylin where she served as an Associate Director, Financial Business Partner leading financial planning and reporting activities for a $300M division. Prior to that, Monica held a variety of finance roles at Invitrogen, Ericsson and Qualcomm. Monica holds a B.S. in Business Administration with an emphasis in accounting from San Diego State University.

CLOSE

Amy Fox

Vice President, Human Resources

READ BIOGRAPHY

Amy Fox  joined Orexigen in 2015, partnering with the Chief Operating Officer and commercial leadership team to stand up the US commercial organization. She built scalable HR capabilities, processes and systems to support rapid growth and led the design and implementation of company’s performance system. Amy currently serves as the Vice President of Human Resources for Nalpropion Pharmaceuticals, Inc and is responsible for Global HR Operations and Business Partner Support.  She has more than 20 years of human resources experience in life sciences and professional services industries.  Prior to her roles at Nalpropion and Orexigen, Amy served in progressively senior roles at Synteract, Robbins Arroyo, LLP and Latham & Watkins, LLP.  Amy received her B.A. from University of California, San Diego.

CLOSE

Amy Halseth

Vice President, Clinical Development

READ BIOGRAPHY

Amy Halseth joined Orexigen in 2012 where she served as the Vice President of Clinical Development and Medical Affairs.  At Nalpropion Pharmaceuticals, Amy will oversee the Global Development, Regulatory, and Pharmacovigilance functions. Amy has over 20 years of experience in the biopharmaceutical industry, having worked in preclinical research, clinical development, and medical affairs roles, and has contributed to regulatory strategy leading to product approvals in the US, Europe, and Canada. Prior to her role at Nalpropion, Amy held positions at Roche/Genentech, Amylin Pharmaceuticals, and Pharmacia, with a focus on obesity and other metabolic diseases. Amy holds a Ph.D. in Molecular Physiology and Biophysics from Vanderbilt University.

CLOSE

Kris Hanson

Vice President, Legal & Compliance

READ BIOGRAPHY

Kris Hanson joined Orexigen Therapeutics in 2016 and currently serves as Vice President, Legal & Compliance for Nalpropion Pharmaceuticals.  Kris has more than 20 years of experience advising public and private companies across multiple industries with respect to corporate governance, capital markets and strategic transactions, commercial contracting and licensing, IP portfolio management, compliance and litigation.  Prior to his roles at Nalpropion and Orexigen, Kris served in progressively senior legal roles at SAIC, Cricket Communications, and Lytx.  Before beginning his in-house career, Kris was in private practice as a corporate lawyer at Morrison & Foerster LLP and Brobeck, Phleger & Harrison LLP, after having served as a judicial law clerk for U.S. District Court Judge John S. Rhoades.  Kris received a B.A. from Georgetown University and a J.D. from the UCLA School of Law.

CLOSE